|
GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includes an upfront payment of $1.2 billion and milestone payments. Efimosfermin, targeting steatotic liver disease and MASH, is expected to launch in 2029, with GSK also planning to explore its use for alcohol-related liver disease.
Category:
News and Media
Britain's competition watchdog wants to review a 3.7bn deal that would see Aviva takeover Direct Line.
Category:
News and Media
Donald Trump met Ahmad al-Sharaa, Syria's interim President. This is the first meeting between the two nations' leaders in 25 years. The U.S. plans to lift economic sanctions on Syria. Syrians celebrated the news, hopeful for economic recovery. Al-Sharaa became interim president after an offensive by his group, Hayat Tahrir al-Sham. Gulf Arab leaders support the new government.
Category:
News and Media
All news |
||||||||||||||||||
|